Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism
NCT ID: NCT04246073
Last Updated: 2020-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2019-02-01
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is a cohort study, recruiting cancer patients over 18 years of age, who have been diagnosed with cancer for over a period of one year.
Exclusion criteria apply as well while all patients can withdraw their participation at any time point.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy or pregnancy
* Patients on long-term anticoagulation for any reason (MKH, HMB or ABK, DOACs) at prophylactic or therapeutic dose, prior to enrollment in the study.
* Active haemorrhage, diagnosed hemorrhagic disorder, thrombocytopenia
* Ulcers or vasodilatations of the gastrointestinal tract
* Hemorrhagic stroke or surgery in the brain, spine or eye of the last trimester
* Bacterial endocarditis or other contraindication to the use of anticoagulant treatment
* Creatinine clearance \<20mL / min
* Thrombolytic treatment or administration of dextran in the 2 days preceding administration of fondaparinux
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Society of Surgical Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ioannis G Karaitianos
Role: STUDY_DIRECTOR
Hellenic Society of Surgical Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ioannis Karaitianos
Athens, Attica, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ioannis G Karaitianos, Study Director
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1787/11-2-2019
Identifier Type: -
Identifier Source: org_study_id